See: Jitsi Meet Handbook – Developers Self-Hosting Guide
See: https://jitsi.github.io/handbook/docs/devops-guide/devops-guide-videotutorials
Leronlimab is a novel humanized monoclonal antibody that is a CCR5 antagonist with the potential for multiple therapeutic indications, including a therapy for treating Covid-19 Patients. Leronlimab targets and binds to the CCR5 receptor and, for example, inhibits RANTES (CCL5 found in high levels in severe to critical Covid-19 patients) from binding to CCR5 and thereby preventing the formation of chemokines and cytokines that cause the “cytokine storm” which invades the lungs causing severe inflammation and reductions in blood-oxygen levels.
Cytodyn Inc., located in Vancouver, Washington, is a late-stage biotechnology company developing leronlimab.
CytoDyn’s Phase 2b/3 trial to evaluate the efficacy and safety of leronlimab for patients with severe-to-critical COVID-19 indications is a two-arm, randomized, double blind, placebo controlled, adaptive design multicenter study. Patients are randomized to receive weekly doses of 700 mg leronlimab, or placebo. Leronlimab and placebo are administered via subcutaneous injection. The study has three phases: Screening Period, Treatment Period, and Follow-Up Period. The primary outcome measured in this study is: all-cause mortality at Day 28. Secondary outcomes measured are: (1) all-cause mortality at Day 14, (2) change in clinical status of subject at Day 14, (3) change in clinical status of subject at Day 28, and (4) change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.
On October 20, 2020, Cytodyn announced recommendations from the independent Data Safety Monitoring Committee (DSMC) following its review of the interim analysis of the Company’s Phase 2b/3 registrational trial in patients with severe-to-critical COVID-19. The interim analysis was performed on data from the first 195 (50%) of 390 planned patients. The DSMC recommended that the trial continue without modification to achieve the primary endpoint and requests another interim analysis when enrollment reaches 75% level (or 293 patients) to review patient mortality and other clinical outcome data between the two study arms (leronlimab vs. placebo).
Once the SSL certificate is installed, your site still remains accessible via a regular insecure HTTP connection. To connect securely, visitors must specify the https:// prefix manually when entering your site’s address in their browsers.
In order to force a secure connection on your website, it is necessary to set up a certain HTTP/HTTPS redirection rule. This way, anyone who enters your site using a link like “yourdomain.com” will be redirected to “https://yourdomain.com” or “https://www.yourdomain.com” (depending on your choice) making the traffic encrypted between the server and the client side.
Below are steps to setup a IIS HTTPS redirect:
NOTE: There are 4 redirect types of the redirect rule that can be selected in that menu:
– Permanent (301) – preferable type in this case, which tells clients that the content of the site is permanently moved to the HTTPS version. Good for SEO, as it brings all the traffic to your HTTPS website making a positive effect on its ranking in search engines.
– Found (302) – should be used only if you moved the content of certain pages to a new place *temporarily*. This way the SEO traffic goes in favour of the previous content’s location. This option is generally not recommended for a HTTP/HTTPS redirect.
– See Other (303) – specific redirect type for GET requests. Not recommended for HTTP/HTTPS.
– Temporary (307) – HTTP/1.1 successor of 302 redirect type. Not recommended for HTTP/HTTPS.
The IIS redirect can be checked by accessing your site via http:// specified in the URL. To make sure that your browser displays not the cached version of your site, you can use anonymous mode of the browser.
The rule is created in IIS, but the site is still not redirected to https://
[Skip to #6 and #7 Below “SOLVED.” This is my recommended tip which I doubt that you will find elsewhere on the net. You will see the logic.]
Normally, the redirection rule gets written into the web.config file located in the document root directory of your website. If the redirection does not work for some reason, make sure that web.config exists and check if it contains the appropriate rule.
To do this, follow these steps:
<configuration> <system.webServer> <rewrite> <rules> <rule name="HTTPS force" enabled="true" stopProcessing="true"> <match url="(.*)" /> <conditions> <add input="{HTTPS}" pattern="^OFF$" /> </conditions> <action type="Redirect" url="https://{HTTP_HOST}{REQUEST_URI}" redirectType="Permanent" /> </rule> </rules> </rewrite> </system.webServer> </configuration>
If this article helped you and saved considerable time and effort, please consider donating a little something through paypal to support continued hosting of this site. Thank you.
This article applies to Windows XP, 7 and Server 2003. It also works in Server 2008 R2 SP1 when trying to uses Windows Backup with Exchange 2010.
Having trouble running Windows Backup on Windows Server 2008 R2 SP1 with Exchange 2010 Installed? Do you keep getting errors with Backup Failed? See the following URL and the following instructions.
Open a command prompt selecting “Run As Administrator”
Run the command line command:
vss list writers
Write down each writer service that shows an error. Then, match each writer with an error to each Service Name shown in the table at the above URL.
Then, open Administrative Tools, Services, and find each service that you have in your error list, and restart each service that shows an error after you ran the command vss list writers.
Re-run the command vss list writers. Repeat the service restart of each writer with an error.
Reboot if you can’t get rid of all errors.
Run the command vss list writers.
If no error, run Windows Backup.